New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
12:40 EDTARNA, OREX, VVUSVIVUS retreats after analyst cuts rating to sell equivalent
Shares of VIVUS (VVUS), which has developed an anti-obesity drug, are declining after research firm Piper Jaffray downgraded the stock in a note to investors earlier today. WHAT'S NEW: Piper analyst Charles Duncan wrote that he was "increasingly wary" about the outlook for VIVUS' anti-obesity drug, Qsymia. Prescription trends for the drug are "underwhelming," while VIVUS has so far failed to find a U.S. marketing partner for the drug, the analyst explained. Moreover, a competing anti-obesity drug, Orexigen's (OREX) Contrave, is expected to be launched in the second half of this year, Duncan wrote. He now expects VIVUS to generate revenue of $53M for Qsymia, versus what he said was the consensus outlook of $92M. Duncan cut his rating on the stock to Underweight, the equivalent of a sell, from Neutral and slashed his price target on the shares to $3 from $8. WHAT'S NOTABLE: Despite the downgrade, Duncan wrote that he continues to believe the U.S. anti-obesity market outlook is improving. Arena Pharmaceuticals (ARNA) has also developed an anti-obesity drug. Belviq. PRICE ACTION: In early afternoon trading, VIVUS fell 8% to $5.70, Orexigen dropped 4.3% to $6.20, and Arena fell 3.6% to $6.45.
News For VVUS;OREX;ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:28 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
07:21 EDTOREXOrexigen Mysimba receives positive CHMP opinion
Subscribe for More Information
07:20 EDTOREXOrexigen weight loss drug recommended in Europe
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting a marketing authorization for Mysimba for weight management of overweight or obese adults. The medicine is recommended for use in addition to a reduced-calorie diet and physical activity. Mysimba is made by Orexigen.
December 15, 2014
10:10 EDTOREXHigh option volume stocks:
High option volume stocks: RVBD AGCO FRO CRUS UBNT LH PAY PETM OREX KOS
07:35 EDTVVUSApricus Biosciences appoints Barbara Troupin, M.D. as Chief Medical Officer
Subscribe for More Information
December 8, 2014
06:47 EDTARNAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
06:45 EDTARNAArena says Eisai withdraws Belviq application in Canada
Subscribe for More Information
06:44 EDTARNAArena Pharmaceuticals says 'small number' of Belviq labels incomplete
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use